Merck, Novo Nordisk spared from 1,500 suits over diabetes drug blamed for cancer

Novo Nordisk has been let off the hook in multiple lawsuits brought forth by diabetes patients in the US, alleging cancer links with some of Novo’s and also Merck’s diabetes treatments.

Photo: Novo Nordisk / PR

Consumers suing Merck & Co., Novo Nordisk A/S and other makers of diabetes drugs allegedly linked to pancreatic cancer are dropping their complaints, according to an email seen by Bloomberg.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs